Novotech presents research into state of biotech industry

29 December 2023

Singapore-based Novotech, an Asia-Pacific-focused contract research organization (CRO), has presented research on financial shifts in the biotech industry in 2023.

The company said its work represented a “thorough evaluation of the worldwide financial landscape for biotech clinical trials, offering valuable and actionable insights.”

The research identifies a “convergence of diverse factors, including economic pressures, intense competition, ever-evolving market dynamics, and regulatory changes, is reshaping the industry, impacting both agile biotech startups and well-established pharmaceutical giants alike.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK